Business
Result of General Meeting and Change of Name
Result of General Meeting and Change of Name.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 8241D Epistem Holdings plc 11 July 2016 \n\n 11 July 2016\nEpistem Holdings plc (\"Epistem\" or the \"Company\")\nResult of General Meeting and Change of Name\nEpistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed. The Company will within the next 15 days formally change its name to Genedrive plc and the TIDM will change to GDR. The Company will make a further announcement at that time.\nThe full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 23 June 2016 which is available on the Company's website http://www.epistem.co.uk/.\nApplication has been made to AIM, a market of the London Stock Exchange plc, for the admission of 8,125,000 New Ordinary Shares. It is expected that Admission will become effective at 8.00 a.m. on 12 July 2016. Following Admission, the Company will have 18,689,446 Ordinary Shares in issue.\nUnless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.\nFor further details please contact:\n\n\n\n\nEpistem Holdings Plc\n\n\n+44 (0)161 989 0245\n\n\n\n\nDavid Budd: CEO\n\n\n\n\n\n\n\nJohn Rylands: Finance Director\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n+44 (0)207 418 8900\n\n\n\n\nJames Steel\n\n\n\n\n\n\n\nOliver Jackson\n\n\n\n\n\n\n\nSohail Akbar\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nConsilium Strategic Communications\n\n\n+44 (0)203 709 5700\n\n\n\n\nChris Gardner\n\n\n\n\n\n\n\nLaura Thornton\n\n\n\n\n\n\n\[email protected]\n\n\n\n\n\n\n\n \nNotes to Editors\nAbout Epistem\nEpistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and its MTB/RIF test has been launche...